Equillium (0A4D) Price & Analysis

1 Followers

0A4D Stock Chart & Stats

$2.40

-$0.12(-5.00%)

At close: Jul 31 4:00 PM EDT

$2.40

-$0.12(-5.00%)

Day’s Range― - ―

52-Week Range$0.53 - $3.53

Previous CloseN/A

Volume1.91K

Average Volume (3M)1.49K

Market Cap

$139.10M

Enterprise Value$131.93

Total Cash (Recent Filing)$61.32M

Total Debt (Recent Filing)$692.00K

Price to Earnings (P/E)―

Beta0.25

Next Earnings

Aug 12, 2026

EPS Estimate

-0.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.38

Shares Outstanding63,226,555

10 Day Avg. Volume995

30 Day Avg. Volume1,493

Financial Highlights & Ratios

PEG Ratio-0.06

Price to Book (P/B)4.98

Price to Sales (P/S)0.00

P/FCF Ratio-6.25

Enterprise Value/Market Cap<0.01

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit>-0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$9.00

Price Target Upside275.00% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)-0.23

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low LeverageVery low debt levels provide structural financial flexibility for a clinical-stage biotech. With minimal interest obligations, management can prioritize R&D and partnerships without servicing debt, reducing bankruptcy risk and preserving capacity for future financing or strategic deals over months.

Corporate Financing FlexibilityBoard-authorized reverse split range and a doubled authorized share count give long-term tools to manage equity financing and execute strategic transactions. These measures make it easier to raise capital or restructure equity if clinical progress requires sizable funding rounds.

Focused Immunology PipelineA concentrated pipeline targeting T-cell modulation and immune-mediated diseases aligns with structural demand for novel immunotherapies. If clinical outcomes are positive, focused assets can translate to durable franchise value and multiple partnership or commercialization pathways.

Bears Say

Revenue CollapseA near-total loss of revenue indicates the company no longer benefits from prior commercial or partnership inflows, forcing reliance on external funding. Over months this elevates execution risk, complicates sustained R&D spending, and pressures strategic options absent new revenue sources.

High Cash BurnConsistent negative operating and free cash flow at material levels implies ongoing dilution or need for non-dilutive deals. Persistent burn reduces runway without new financing, constraining long-term program advancement and making strategic timing and partner milestones critical over the next several months.

Sustained Losses And Negative ReturnsOngoing net losses and negative ROE reflect inability to generate shareholder returns from current operations. Over a multi-month horizon, this undermines retained capital growth, heightens dependence on capital markets, and may pressure management to pursue dilutionary financings or asset sales.

Equillium News

Equillium initiated with a Buy at Clear Street

Clear Street analyst Kaveri Pohlman initiated coverage of Equillium (EQ) with a Buy rating and $9 price target...

14d ago

Equillium initiated with an Overweight at Piper Sandler

Piper Sandler analyst Yasmeen Rahimi initiated coverage of Equillium (EQ) with an Overweight rating and $20 price target...

22d ago

Equillium Shareholders Approve Reverse Split and Capital Changes

Equillium ( ($EQ) ) has shared an announcement. On May 28, 2026, Equillium, Inc. held its 2026 annual...

2M ago

Equillium price target raised to $7 from $6 at Raymond James

Raymond James raised the firm’s price target on Equillium (EQ) to $7 from $6 and keeps a Strong...

2M ago

Leerink upgrades Equillium on ‘supportive’ ulcerative colitis data

Leerink upgraded Equillium (EQ) to Outperform from Market Perform with a price target of $6, up from $1....

2M ago

Equillium upgraded to Outperform from Market Perform at Leerink

Leerink upgraded Equillium (EQ) to Outperform from Market Perform with a $6 price target Published first on TheFly...

2M ago

Equillium: Compliance, Operational and Market Risks Cloud Long-Term Outlook for Shareholders

Equillium (EQ) has disclosed a new risk, in the Regulation category. Equillium faces ongoing exposure to U.S. public...

3M ago

Equillium reports Q1 EPS (6c), consensus (4c)

“Following our March year-end update and financing, we have remained focused on advancing EQ504 toward the clinic while...

3M ago

Equillium appoints Snehal Naik as chief development officer

Equillium (EQ) appointed Snehal Naik as chief development officer. Naik will lead clinical development and medical strategy across...

3M ago

Equillium initiated with an Outperform at Oppenheimer

Oppenheimer initiated coverage of Equillium (EQ) with an Outperform rating and $7 price target The firm is positive...

3M ago

Equillium initiated with a Buy at B. Riley

B. Riley analyst William Wood initiated coverage of Equillium (EQ) with a Buy rating and $6 price target...

4M ago

Equillium initiated with a Strong Buy at Raymond James

Raymond James initiated coverage of Equillium (EQ) with a Strong Buy rating and $6 price target Lead asset...

4M ago

EQ Upcoming Earnings Report: What to Expect?

Equillium (EQ) is scheduled to report 4th quarter earnings on 03/26/2026. Regarding Q4 estimates, Wall Street analysts expect...

4M ago

Equillium Raises Capital Through Private Equity Securities Sale

Equillium ( ($EQ) ) just unveiled an announcement. On March 11, 2026, Equillium, Inc. entered into a securities...

5M ago

0A4D FAQ

What was Equillium Inc’s price range in the past 12 months?

Equillium Inc lowest share price was $0.53 and its highest was $3.53 in the past 12 months.

What is Equillium Inc’s market cap?

Equillium Inc’s market cap is $139.10M.

When is Equillium Inc’s upcoming earnings report date?

Equillium Inc’s upcoming earnings report date is Aug 12, 2026 which is in 8 days.

How were Equillium Inc’s earnings last quarter?

Equillium Inc released its earnings results on May 13, 2026. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.046 by -$0.014.

Is Equillium Inc overvalued?

According to Wall Street analysts Equillium Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Equillium Inc pay dividends?

Equillium Inc does not currently pay dividends.

What is Equillium Inc’s EPS estimate?

Equillium Inc’s EPS estimate is -0.05.

How many shares outstanding does Equillium Inc have?

Equillium Inc has 63,226,555 shares outstanding.

What happened to Equillium Inc’s price movement after its last earnings report?

Equillium Inc reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.046. Following the earnings report the stock price went up 7.273%.

Which hedge fund is a major shareholder of Equillium Inc?

Currently, no hedge funds are holding shares in GB:0A4D

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Equillium Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

277.09%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Equillium Inc

Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.

Equillium (0A4D) Earnings & Revenues

Historic Earnings Reports

0A4D Stock 12 Month Forecast

Average Price Target

$9.00

▲(275.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","21":"$21","-1":"-$1","4.5":"$4.5","15.5":"$15.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,4.5,10,15.5,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.28,3.643076923076923,5.006153846153846,6.36923076923077,7.7323076923076925,9.095384615384615,10.458461538461538,11.821538461538461,13.184615384615384,14.547692307692307,15.91076923076923,17.273846153846154,18.63692307692308,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.28,2.796923076923077,3.3138461538461534,3.8307692307692305,4.3476923076923075,4.864615384615385,5.381538461538462,5.898461538461538,6.415384615384616,6.932307692307692,7.44923076923077,7.966153846153846,8.483076923076922,{"y":9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.28,2.489230769230769,2.6984615384615385,2.9076923076923076,3.1169230769230767,3.3261538461538462,3.5353846153846153,3.7446153846153845,3.953846153846154,4.163076923076924,4.372307692307692,4.581538461538461,4.7907692307692304,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.801,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.64,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.475,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.425,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.901,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.525,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.548,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.78,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.04,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.07,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.91,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.12,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.28,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >